Removal of gelatin from live vaccines and DTaP—an ultimate solution for vaccine-related gelatin allergy

Anaphylaxis following quadrivalent human papillomavirus vaccination

“…The rate of anaphylaxis after HPV vaccination is comparable only to the rate following administration of vaccines containing bovine gelatin in Japan (Table 2), which led to removal of the gelatin from the vaccine. 17 The lower limit of the confidence interval for the rate of anaphylaxis in the New South Wales HPV vaccination program overlaps with the upper limit of the confidence interval for the Canadian hepatitis B vaccination program and UK measles-rubella vaccination program (Table 2). Although the point estimate for the rate of anaphylaxis is higher than in previous programs, the estimated rate is still an order of magnitude less common than the World Health Organization categorization of adverse events after immunization which are "very rare" (< 1 in 10 000).…”

“…The median age was 16.5 (min-max [15][16][17][18][19][20][21][22][23][24][25] years. Six cases were reported after dose 1 of the vaccine, and …”

“…This program, part of a national campaign to avert a further increase in cases of meningococcal C disease in Australia, administered 823 197 doses of vaccine to boys and girls aged [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] years. This panel classified relevant adverse events as anaphylaxis (n = 1), allergic reaction (n = 13) or rash (n = 10); there were 4 children who received adrenaline (New South Wales Health, unpublished data).…”

The complex link between immunization against childhood diseases and allergy

“…The IgE-dependent allergic reactions to the gelatine [12][13][14] and the neomycin contained in MMR are more frequent than the allergic reactions related to the presence of egg proteins (negligible quantity) in this vaccine. Other gelatine-containing vaccines are those against chickenpox and Japanese encephalitis and, in Japan, associated vaccines including the diphtheria, tetanus, pertussis (whooping cough/Bordetella pertussis) and polio (DTP-polio)/Tétracoq [15].…”

Classical Live Viral Vaccines

“…In general, these requirements specify that the vaccine must retain minimum potency and not lose more than a specified amount (e.g., 0.5 or 1 log 10 ) under accelerated conditions (exposure at 37 C temperature) for a specified length of time which may be as short as 2 days (polio) or as long as 30 days (smallpox). Excipients used by some manufacturers to stabilize live vaccines, in particular hydrolyzed porcine gelatin [67], can be responsible for allergic adverse events.…”